Does Blue Cross Blue Shield of Arizona Cover Prolia?

What Is Prolia and Why Does Insurance Scrutinize It?

Prolia is a biologic RANK ligand inhibitor that the FDA approved on June 1, 2010, for postmenopausal women with osteoporosis at high fracture risk, men with osteoporosis, and patients on glucocorticoid therapy or undergoing androgen deprivation therapy for prostate cancer [1]. Because it costs roughly $1,400 to $1,600 per dose at U.S. retail pharmacies and is administered only twice per year, insurers classify it as a specialty medication subject to strict utilization management.

The key FREEDOM trial (N=7,868) demonstrated that denosumab 60 mg every 6 months reduced the relative risk of new vertebral fractures by 68 percent (RR 0.32 to 95% CI 0.26 to 0.41, P<0.001) over 36 months compared with placebo in postmenopausal women with a lumbar spine or total hip T-score between -2.5 and -4.0 [2]. Hip fracture risk fell by 40 percent (RR 0.60 to 95% CI 0.37 to 0.97, P<0.04) [2]. Those numbers are why clinicians consider Prolia a first-line option for high-risk patients, yet they also explain why BCBSAZ requires documentation that the clinical need genuinely meets that high-risk threshold before approving the drug.

The American Association of Clinical Endocrinology (AACE) 2020 Clinical Practice Guidelines state that denosumab is appropriate for patients with a T-score of -2.5 or below, or for those with prior fragility fracture, or for those with a 10-year FRAX hip fracture probability at or above 3 percent or major osteoporotic fracture probability at or above 20 percent [3]. BCBSAZ prior authorization criteria mirror this language closely.

Does BCBSAZ Actually Cover Prolia on Its Formulary?

Yes, BCBSAZ includes denosumab (Prolia) on its formulary for commercial, individual, and Medicare Advantage plans. The drug typically sits at Specialty Tier 4 or Tier 5, which means cost-sharing is the highest in the plan's tier structure. Without hitting your deductible, you may owe a percentage coinsurance (commonly 20 to 30 percent) rather than a flat copay.

BCBSAZ administers its pharmacy benefits through its own pharmacy benefit management arm and, for some employer groups, through a contracted PBM. The specific formulary tier can differ between your employer's group plan, an ACA marketplace plan, and an ArizonaCare or Medicare Advantage product. Always confirm the exact tier by logging into your BCBSAZ member portal or calling the number on the back of your ID card before the first injection is ordered.

Under the Affordable Care Act's essential health benefits framework, plans cannot exclude osteoporosis drugs categorically. The FDA's guidance on specialty biologics does not set a coverage mandate, but it does establish the safety and efficacy record that supports medical necessity arguments during appeals [4]. The U.S. Preventive Services Task Force (USPSTF) recommends osteoporosis screening in women aged 65 and older, and in younger postmenopausal women with equivalent fracture risk, which creates a documented clinical pathway that feeds into coverage decisions [5].

Prior Authorization: What BCBSAZ Typically Requires

Prior authorization (PA) is the biggest hurdle. Your prescribing physician must submit a PA request before BCBSAZ will pay for the injection. The request generally must include all of the following elements.

Documented diagnosis. An ICD-10 code for osteoporosis (M81.0 for age-related osteoporosis without current pathological fracture being the most common) paired with a DEXA scan result showing a T-score at or below -2.5 at the lumbar spine or femoral neck. Some plans accept T-scores between -1.0 and -2.5 (osteopenia) if a FRAX 10-year probability calculation meets threshold [3].

Step therapy documentation. BCBSAZ commercial plans typically require a trial of at least one oral bisphosphonate, most often alendronate (Fosamax) 70 mg weekly or risedronate (Actonel) 35 mg weekly, for a minimum of 6 to 12 months. The Endocrine Society's 2019 Pharmacological Management of Osteoporosis guideline identifies bisphosphonates as preferred first-line therapy for most patients without contraindications, which is the clinical basis for this step [6]. If the patient had a documented GI adverse event, renal insufficiency (CrCl <35 mL/min), or prior atypical femoral fracture on a bisphosphonate, step therapy can generally be bypassed with adequate documentation.

Prescriber specialty. Many BCBSAZ PA policies give preference to requests from endocrinologists, rheumatologists, or obstetrician-gynecologists who manage osteoporosis regularly, though primary care physicians can also submit.

Frequency limit. Coverage is typically limited to one 60 mg injection every 180 days (6 months), matching the FDA-approved dosing interval [1].

Once submitted, BCBSAZ is required under Arizona state insurance law to respond to standard PA requests within 3 business days and to urgent requests within 24 hours [7].

Step Therapy in Detail: The Bisphosphonate Requirement

Step therapy is effectively a requirement to try a cheaper drug first. For Prolia, that means bisphosphonates. Alendronate 70 mg taken once weekly remains the most commonly prescribed option; generic alendronate costs as little as $4 to $10 per month at major pharmacy chains, making it a logical cost-management tool for insurers.

The clinical rationale has real merit. The FIT trial (N=2,027) showed alendronate 5 mg or 10 mg daily reduced vertebral fracture risk by 47 percent (RR 0.53 to 95% CI 0.41 to 0.68) in women with existing vertebral fractures over 3 years [8]. For patients who actually tolerate bisphosphonates, the drugs work.

The step therapy exemption pathway matters enormously. Under Arizona's step therapy law (A.R.S. § 20-3321), an insurer must grant an exemption when a patient has already tried the required drug and it was contraindicated, caused an adverse reaction, or was clinically ineffective. Your physician should document all of the following in the exemption request: the specific bisphosphonate tried, the dose, the duration, the reason for failure or intolerance, and relevant lab values such as creatinine clearance if renal insufficiency is cited.

Risedronate (Actonel) is sometimes used as an alternative step when alendronate causes esophageal or GI irritation. Zoledronic acid (Reclast) 5 mg IV once yearly may also satisfy step therapy requirements on some BCBSAZ plans, and it carries the same fracture-reduction evidence base [8].

Medicare Advantage Plans Through BCBSAZ

BCBSAZ offers several Medicare Advantage (MA) plans in Arizona counties. Prolia coverage under MA follows CMS guidelines rather than commercial insurance rules. CMS's Part D drug formulary requirements classify Prolia as a Part D covered drug when dispensed at a pharmacy, or potentially as Part B when administered in a physician's office as an injectable.

This Part B versus Part D distinction is clinically significant. If your physician administers the injection in the office, BCBSAZ Medicare Advantage may process it under Part B as a physician-administered biologic. Part B cost-sharing is typically 20 percent coinsurance after the Part B deductible ($240 in 2024). Under Part D specialty tier cost-sharing, the amount owed varies by plan.

CMS requires Medicare Advantage plans to include denosumab on their formularies due to its protected class status in most plan designs. The Low Income Subsidy (LIS, also called Extra Help) can reduce Part D specialty drug costs to a few dollars per month for qualifying beneficiaries [9]. The CMS Medicare Prescription Drug Benefit manual outlines LIS eligibility and cost-sharing caps relevant to high-cost biologics [9].

What Prolia Costs Without Insurance in Arizona

Without coverage, Prolia's retail price in Arizona runs $1,400 to $1,600 per 60 mg/mL prefilled syringe. Because only one injection is given every 6 months, the annual out-of-pocket cost without insurance is approximately $2,800 to $3,200.

The manufacturer, Amgen, runs the Prolia SupportPlus program. Commercially insured patients who meet income criteria may qualify for a $0 copay per injection. The program does not apply to Medicare, Medicaid, or any government-funded plan. Patients can enroll at 1-800-772-6436 or through Amgen's patient assistance portal.

For uninsured patients with household income at or below 500 percent of the federal poverty level, Amgen's Needy Meds program may provide Prolia at no cost. NeedyMeds.org also maintains a database of state and local assistance programs in Arizona that cover bone-loss treatment.

Goodrx and similar discount platforms typically cannot match the manufacturer assistance program for Prolia because the drug's brand status and distribution channel limit discount card application. This is one case where going directly to Amgen's support line usually produces the lowest out-of-pocket amount.

How to Handle a Prior Authorization Denial

BCBSAZ denies some first-time Prolia PA requests, usually because documentation was incomplete or step therapy was not adequately satisfied. A denial is not necessarily final.

Step 1. Read the denial letter carefully. BCBSAZ must provide a written explanation of the specific clinical criteria that were not met. Arizona law (A.R.S. § 20-3321) requires this disclosure.

Step 2. File an internal appeal immediately. You have 180 days from the denial date to file an internal appeal on most commercial BCBSAZ plans. Your physician's office should lead this process, adding any missing DEXA scan reports, FRAX scores, lab results, or bisphosphonate trial documentation.

Step 3. Request a peer-to-peer review. Your physician can request a direct call with BCBSAZ's medical reviewer. Studies on insurer appeal processes suggest that peer-to-peer conversations resolve a meaningful share of PA disputes without formal escalation. A 2017 analysis published in Health Affairs found that physician-led appeals overturned approximately 39 percent of specialty drug denials on the first internal review cycle [10].

Step 4. File an external review if needed. If the internal appeal fails, Arizona law allows an independent external review through the Arizona Department of Insurance and Financial Institutions. The external reviewer is a board-certified physician not employed by BCBSAZ.

Step 5. Ask your physician about medical exception. If Prolia is medically necessary and alternatives are contraindicated, a formal medical exception request, supported by peer-reviewed literature such as the FREEDOM trial data [2] and AACE guidelines [3], can sometimes succeed where a standard PA fails.

Alternatives BCBSAZ May Approve More Easily

If Prolia's prior authorization process is prolonged, several alternatives carry strong evidence and simpler formulary positioning on most BCBSAZ plans.

Alendronate (generic Fosamax) 70 mg weekly is typically on Tier 1 or Tier 2 with no prior authorization required. The FIT trial established its vertebral fracture benefit [8], and its generic cost means BCBSAZ has minimal financial incentive to restrict it.

Zoledronic acid (Reclast) 5 mg IV once yearly is usually covered under the medical benefit rather than the pharmacy benefit, which changes the PA pathway. The HORIZON Key Fracture Trial (N=7,765) showed a 70 percent relative risk reduction in new vertebral fractures and a 41 percent reduction in hip fractures versus placebo over 3 years [11].

Raloxifene (Evista) 60 mg daily is a selective estrogen receptor modulator indicated for postmenopausal osteoporosis prevention and treatment. The MORE trial (N=7,705) demonstrated a 30 percent reduction in clinical vertebral fractures over 3 years [12]. It does not reduce hip fracture risk, which limits its utility in the highest-risk patients.

Romosozumab (Evenity) 210 mg monthly subcutaneous injection is a sclerostin inhibitor approved in 2019 for women with osteoporosis at very high fracture risk. The ARCH trial (N=4,093) showed romosozumab followed by alendronate reduced vertebral fracture risk by 48 percent relative to alendronate alone over 24 months [13]. BCBSAZ restricts romosozumab at least as heavily as Prolia, so it is not a simpler alternative from a coverage standpoint.

For patients with severe osteoporosis or multiple prior fractures, teriparatide (Forteo) or abaloparatide (Tymlos) are anabolic agents that may be approved when antiresorptive therapy has failed. Both require PA, but the clinical criteria differ from Prolia's.

BCBSAZ Coverage for Related Prolia Indications

Prolia has FDA-approved indications beyond postmenopausal osteoporosis. BCBSAZ coverage criteria differ by indication.

Men with osteoporosis. FDA-approved since 2012. BCBSAZ typically covers with PA using the same T-score and FRAX thresholds as postmenopausal women.

Glucocorticoid-induced osteoporosis (GIOP). Patients on prednisone 7.5 mg or more daily for 6 months or longer qualify for GIOP diagnosis. The ACR 2022 Guideline for the Prevention and Treatment of GIOP supports denosumab as an option for high-risk patients when oral bisphosphonates are not tolerated [14]. BCBSAZ may accept ongoing high-dose glucocorticoid use as sufficient to bypass bisphosphonate step therapy in GIOP cases.

Bone loss from androgen deprivation therapy (ADT) in prostate cancer. Men receiving ADT for nonmetastatic prostate cancer are at high risk for osteoporosis and fracture. BCBSAZ PA criteria for this indication usually require documented ADT use and a T-score at or below -1.0, a lower threshold than standard osteoporosis criteria.

Bone loss from aromatase inhibitor (AI) therapy in breast cancer. Similar to ADT, AI-associated bone loss in women with breast cancer can qualify for Prolia coverage with documentation of AI use and BMD values.

Coverage for the oncology-adjacent indications sometimes flows through the oncology prior authorization pathway rather than the standard pharmacy PA pathway, which may involve the patient's oncologist submitting documentation rather than the primary care physician.

Practical Steps to Maximize Your Approval Odds

Getting Prolia approved by BCBSAZ follows a predictable checklist. The physician's office carries most of the administrative weight, but patients who understand the process get approvals faster.

First, confirm that your DEXA scan was performed within the last 24 months and that the report clearly states the T-score at both the lumbar spine (L1 to L4) and the total hip or femoral neck. BCBSAZ reviewers will reject PA requests that cite outdated BMD values.

Second, ask your physician to calculate your FRAX score at the time of the PA submission and include it in the clinical notes. The WHO Fracture Risk Assessment Tool (FRAX) provides a 10-year probability estimate for major osteoporotic fracture and hip fracture based on clinical risk factors with or without BMD [15]. A hip fracture probability at or above 3 percent or major osteoporotic fracture probability at or above 20 percent satisfies National Osteoporosis Foundation high-risk criteria and mirrors the AACE guideline language [3].

Third, document any prior bisphosphonate trial explicitly: drug name, dose, start date, end date, and reason for stopping. A vague note stating "patient tried Fosamax in the past" will not satisfy step therapy documentation requirements. The BCBSAZ medical reviewer needs specifics.

Fourth, if your physician is a specialist (endocrinologist, rheumatologist, or gynecologist with documented osteoporosis management experience), make sure that credential is visible in the PA submission. Specialist-submitted requests carry slightly more weight in peer-to-peer review scenarios.

Fifth, submit the PA before scheduling the injection appointment. Pharmacies and infusion centers administering Prolia without confirmed PA approval will bill you at the full retail rate, and retroactive PA approval is not guaranteed under BCBSAZ policy.

Patients with a T-score at or below -3.0 or a prior low-trauma hip or vertebral fracture, the groups most likely to receive immediate BCBSAZ approval, should still follow this checklist because complete documentation cuts turnaround time from the standard 3-business-day window to as little as 24 hours in some cases.